Yuichiro Kaneko - Concepedia

Author

Yuichiro Kaneko

Astellas Pharma (Japan)ORCID

Also Known As

Y Kaneko, Y. Kaneko, Yuichiro KANEKO, Yuichiro Kaneko, Yusuke Kaneko

105

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Astellas Pharma (Japan)University of Occupational and Environmental Health Japan Keio University The University of Tokyo Astellas Pharma (United States)

About

Yuichiro Kaneko is an author at Astellas Pharma (Japan) specializing in transportation engineering, business, and urban planning.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Business	3	3	88
2	Medicine	2	2	28
3	Engineering	1	1	13
4	Natural Sciences	1	1	13
5	Social Sciences	1	1	22

Yuichiro Kaneko

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Intramuscular Transplantation of G-CSF-Mobilized CD34+ Cells in Patients With Critical Limb Ischemia: A Phase I/IIa, Multicenter, Single-Blinded, Dose-Escalation Clinical Trial Atsuhiko Kawamoto, Minako Katayama, Nobuhiro Handa, Stem Cells	2009	246
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study Tsutomu Takeuchi, Yoshiya Tanaka, Manabu Iwasaki, Annals of the Rheumatic Diseases	2015	143
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Annals of the Rheumatic Diseases	2019	124
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3) Yoshiya Tanaka, Tsutomu Takeuchi, Sakae Tanaka, Annals of the Rheumatic Diseases	2019	103
Areas of Nonperfusion in Peripheral Retina of Eyes With Pathologic Myopia Detected by Ultra-Widefield Fluorescein Angiography Yuichiro Kaneko, Muka Moriyama, Shuichiro Hirahara, Investigative Ophthalmology & Visual Science	2014	82
SIX-YEAR OUTCOMES OF INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA Kaori Kasahara, Muka Moriyama, Kei Morohoshi, Retina	2016	57
Comparative analysis of transit assignment: evidence from urban railway system in the Tokyo Metropolitan Area Hironori Kato, Yuichiro Kaneko, Masashi Inoue Transportation Public TransportTransport Network AnalysisBusinessLogisticsUrban Planning	2010	50
Randomized Controlled Trial of Bixalomer Versus Sevelamer Hydrochloride in Hemodialysis Patients With Hyperphosphatemia Tadao Akizawa, Hideki Origasa, Chisato Kameoka, Therapeutic Apheresis and Dialysis	2013	35
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Arthritis Research & Therapy	2020	29
FIVE-YEAR OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA Yuka Onishi, Tae Yokoi, Kaori Kasahara, Retina	2018	26

Page 1